Small Gary W, Siddarth Prabha, Silverman Daniel H S, Ercoli Linda M, Miller Karen J, Lavretsky Helen, Bookheimer Susan Y, Huang S-C, Barrio Jorge R, Phelps Michael E
Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at the University of California, Los Angeles, CA 90024, USA.
Am J Geriatr Psychiatry. 2008 Dec;16(12):999-1009. doi: 10.1097/JGP.0b013e31818cd3a4.
Because anti-inflammatory drugs may delay cognitive decline and influence brain metabolism in normal aging, the authors determined the effects of the cyclooxygenase-2 inhibitor, celecoxib, on cognitive performance and regional cerebral glucose metabolism in nondemented volunteers with mild age-related memory decline.
Randomized, double-blind, placebo-controlled, parallel group trial with 18-months of exposure to study medication.
University research institute.
Eighty-eight subjects, aged 40-81 years (mean: 58.7, SD: 8.9 years) with mild self-reported memory complaints but normal memory performance scores were recruited from community physician referrals, media coverage, and advertising. Forty subjects completed the study.
Daily celecoxib dose of 200 or 400 mg, or placebo.
Standardized neuropsychological test battery and statistical parametric mapping (SPM) of FDG-PET scans performed during mental rest.
Measures of cognition showed significant between-group differences in executive functioning (F [1, 30] = 5.06, p = 0.03) and language/semantic memory (F [1, 31] = 6.19, p = 0.02), favoring the celecoxib group compared with the placebo group. Concomitantly, FDG-PET scans demonstrated bilateral metabolic increases in prefrontal cortex in the celecoxib group in the vicinity of Brodmann's areas 9 and 10, but not in the placebo group. SPM analyses of the PET data pooled by treatment arm corresponded to a 6% increase in activity over pretreatment levels (p <0.01, after adjustment for multiple comparisons).
These results suggest that daily celecoxib use may improve cognitive performance and increase regional brain metabolism in people with age-associated memory decline.
由于抗炎药物可能延缓认知衰退并影响正常衰老过程中的脑代谢，作者确定了环氧化酶-2抑制剂塞来昔布对患有轻度年龄相关性记忆衰退的非痴呆志愿者认知表现和局部脑葡萄糖代谢的影响。
随机、双盲、安慰剂对照、平行组试验，受试者接受18个月的研究药物治疗。
大学研究机构。
从社区医生转诊、媒体报道和广告中招募了88名年龄在40 - 81岁（平均：58.7岁，标准差：8.9岁）的受试者，他们自我报告有轻度记忆问题，但记忆表现评分正常。40名受试者完成了研究。
每日服用200或400毫克塞来昔布，或安慰剂。
在静息状态下进行的标准化神经心理测试组套以及氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）的统计参数映射（SPM）。
认知测量显示，在执行功能（F [1, 30] = 5.06，p = 0.03）和语言/语义记忆方面（F [1, 31] = 6.19，p = 0.02），组间存在显著差异，与安慰剂组相比，塞来昔布组表现更优。同时，FDG-PET扫描显示，塞来昔布组在布罗德曼9区和10区附近的前额叶皮质出现双侧代谢增加，而安慰剂组未出现。按治疗组汇总的PET数据的SPM分析显示，与治疗前水平相比，活动增加了6%（经多重比较调整后，p <0.01）。
这些结果表明，每日使用塞来昔布可能改善与年龄相关的记忆衰退人群的认知表现并增加局部脑代谢。
